ImmunityBio (NASDAQ:IBRX) Trading 5.1% Higher

ImmunityBio, Inc. (NASDAQ:IBRXGet Free Report)’s stock price rose 5.1% on Tuesday . The stock traded as high as $6.22 and last traded at $6.13. Approximately 1,377,064 shares were traded during mid-day trading, a decline of 75% from the average daily volume of 5,576,763 shares. The stock had previously closed at $5.83.

Wall Street Analyst Weigh In

Separately, Piper Sandler raised their price objective on ImmunityBio from $5.00 to $6.00 and gave the company a “neutral” rating in a research note on Monday, April 29th.

Read Our Latest Analysis on ImmunityBio

ImmunityBio Stock Up 6.9 %

The firm has a 50 day moving average of $6.68 and a two-hundred day moving average of $5.28. The firm has a market capitalization of $4.31 billion, a price-to-earnings ratio of -5.65 and a beta of 1.03.

ImmunityBio (NASDAQ:IBRXGet Free Report) last posted its earnings results on Thursday, May 9th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.04). The business had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.03 million. Sell-side analysts forecast that ImmunityBio, Inc. will post -0.75 EPS for the current fiscal year.

Hedge Funds Weigh In On ImmunityBio

Large investors have recently modified their holdings of the business. Vanguard Personalized Indexing Management LLC bought a new position in ImmunityBio during the 3rd quarter worth $37,000. Blair William & Co. IL boosted its holdings in ImmunityBio by 200.7% in the third quarter. Blair William & Co. IL now owns 162,462 shares of the company’s stock valued at $275,000 after acquiring an additional 108,431 shares during the last quarter. WINTON GROUP Ltd bought a new position in ImmunityBio during the 3rd quarter worth approximately $26,000. Rathbones Group PLC bought a new position in ImmunityBio during the 3rd quarter worth approximately $124,000. Finally, Armistice Capital LLC bought a new position in ImmunityBio during the 3rd quarter worth approximately $5,874,000. Institutional investors own 8.58% of the company’s stock.

About ImmunityBio

(Get Free Report)

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.

Read More

Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.